and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. Item 9.01 | Financial Statements and Exhibits. (d) Exhibits Exhibit No. | Description 99.1 | Press Release dated November 5, 2026. 104 | Cover Page…

Chief Medical Officer — Susan G. Kozauer: The filing announces the appointment of a new external Chief Medical Officer, which is a significant addition to the management team rather than a departure.

CFO — Joseph M. Miller: The filing announces the appointment of an external candidate as CFO, which is a new hire rather than a departure of a sitting executive.

Results of Operations and Financial Condition. On August 11, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or other…

Regulation FD Disclosure. On July 29, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The inf…

The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising. Neither this Current Report on Form 8-K nor any exhibit attached here…

Entry into a Material Definitive Agreement. On July 28, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,577,560 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants…

Chief Medical Officer — Anna Eramo, M.D.: Dr. Anna Eramo resigned from her position as Chief Medical Officer for personal reasons and will transition to an advisor role.

Results of Operations and Financial Condition. On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwi…

Results of Operations and Financial Condition. On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

Director — Zachary Prensky: Mr. Prensky is retiring as a member of the Board and will not stand for reelection at the 2026 Annual Meeting.

Chief Operating and Business Officer — Gad Soffer: Mr. Soffer was promoted to Chief Operating and Business Officer with an increased salary and bonus eligibility.

Entry into a Material Definitive Agreement. On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warra…

Regulation FD Disclosure. On February 5, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The…

The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each of the Investors has provided representations appropriate for a private placement of securities. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising. Neither this Current Report on Form 8-K nor any exhibit attached here…

Entry into a Material Definitive Agreement. On November 10, 2025, LB Pharmaceuticals Inc (the “Company”) entered into a First Amendment of Lease (the “Lease Amendment”), which amends that certain Lease Agreement with One Penn Plaza LLC (the “Landlord”), dated as of May 20, 2024, as amended (the “Lease”), providing for the lease of an additional 4,634 rentable square feet (the “Expansion Premises”) on the 10 th floor of a building located at One Penn Plaza, New York, New York 10119. The term o…

Results of Operations and Financial Condition. On November 6, 2025, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or…